Table 1.

CAR T-cell therapies approved by the US Food and Drug Administration (FDA).[7] Abbreviations: ALL, acute lymphoblastic leukemia; DLBCL, diffuse large B-cell lymphoma

CAR T-cell therapy	FDA-approved treatment
Tisagenlecleucel (tisa-cel)	Patients up to 25 years of age with B-cell precursor ALL that is refractory, or in second or later relapse. Adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy including DLBCL not otherwise specified, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma.
Axicabtagene ciloleucel (axi-cel)	Adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including DLBCL not otherwise specified, primary mediastinal large B-cell lymphoma, high-grade B-cell lymphoma, and DLBCL arising from follicular lymphoma. Adult patients with relapsed or refractory follicular lymphoma after two or more lines of systemic therapy.
Lisocabtagene maraleucel (liso-cel)	Adult patients with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy, including DLBCL not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma Grade 3B.
Brexucabtagene autoleucel (brexu-cel)	Adult patients with relapsed or refractory mantle cell lymphoma.
Idecabtagene vicleucel (ide-cel)	Adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therapy, including an immunomodulatory agent, a proteasome inhibitor, and an anti-CD38 monoclonal antibody.